ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients

Featured News

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 05 Aug 2020 10:25 PM | Eric Wenzler (Administrator)

    Congratulations to the Newly Elected SIDP Board Members for 2020–2021! 

    Scott Bergman

    Erin McCreary

    Board Member-at-Large
    Meghan Jeffres

    The SIDP Board of Directors and Nominations and Bylaws Committee would like to thank all of the extremely qualified members who ran in the 2020 election for President-Elect, Treasurer, and Board Member-at-Large. We appreciate your commitment to SIDP and advancing our profession. Additionally, we would like to thank everyone for participating in the election and to our Website and Social Media Committees for their assistance. Please join us in congratulating these individuals!

    On Behalf of the SIDP Nominations and Bylaws Committee

    Chair: Cynthia Nguyen
    Vice Chair: Wesley Kufel
    Immediate Past-Chair: Brandon Dionne
    Board Liaison: Kerry LaPlante
    Committee Members: Karrine Brade, Lindsey Childs-Kean, Monica Mahoney, Brian Potoski, Jenny Shroba, Melissa Steenhoek

  • 21 Apr 2020 7:20 PM | Eric Wenzler (Administrator)

    Today, the National Institute of Health (NIH) released the COVID-19 treatment guidelines, available at The NIH COVID-19 Treatment Guideline is a living document that will be updated as new information becomes available. 

    The Society of Infectious Diseases Pharmacists President-Elect Susan Davis represents SIDP on the treatment guideline panel. The panel was convened urgently in late March and includes clinicians with expertise in infectious diseases, critical care, emergency medicine, and pharmacy. Dr. Davis is one of six clinical pharmacists on the panel, joining others from federal agencies and the Society of Critical Care Medicine. 

    "I'm honored to work with this diverse group of clinicians and scientists on the treatment guidelines panel. The pharmacy team has been working nonstop to critically evaluate emerging literature and provide pharmacotherapy expertise," says Dr. Davis. "These guidelines will provide essential information for healthcare professionals trying to understand the rationale and limitations of proposed COVID-19 therapies."

    "We are very pleased to have SIDP represented on the NIH COVID-19 Treatment Guidelines Panel. SIDP members around the country have been working with their colleagues and communities to design local treatment guidelines, facilitate access to therapies, and educate patients and staff. ID pharmacists provide unique expertise and perspective that is crucial during this ongoing pandemic. We applaud the National Institutes of Health for recognizing and seeking out this expertise," said SIDP President Jason Pogue. 

    Further information from the NIH regarding these guidelines is available here.

    Please visit for additional educational offerings and resources from SIDP related to COVID-19.

  • 07 Jan 2020 2:12 PM | Eric Wenzler (Administrator)

    Dear Friends and Colleagues,   

    It is with great sadness we share that Dr. Amy Pakyz, Pharm.D., M.S., Ph.D., and SIDP Board Member at Large (2017-2019) has passed away.  Amy was an Associate Professor of Pharmacy at Virginia Commonwealth University (VCU) with an international reputation for her work in infectious diseases epidemiology.

    In Amy’s short career, she created a legacy for herself and for the ID pharmacy family.  Amy started her career as an Infectious Diseases fellow with Ron Polk.   After fellowship, Amy left VCU for University of Virginia (UVA) and then returned to VCU in a faculty role in the early 2000s. While a full-time faculty member she received her Master’s in Health Evaluation Science at UVA in 2003, and then her PhD in Health Services Organization & Research at VCU in 2013.   Amy received funding from AHRQ and CDC for research related to antimicrobial stewardship and utilization measurement as well as examining the incidence of and risk factors for C. difficile infection.  She authored over 60 peer-reviewed articles and book chapters.   One of Amy’s most significant contributions was her 2008 Archives of Internal Medicine paper “Trends in Antibacterial Use in US Academic Health Centers 2002 to 2006” describing increasing use of antibiotics driven by broad-spectrum agents and vancomycin. 

    A proud SIDP member since 1996, Amy served the Society as chairperson, vice-chair or member on nearly every SIDP committee.  Amy was also highly involved with SIDP-partner organizations, including serving on SHEA’s Antimicrobial Stewardship Committee, the Vizient Antimicrobial Stewardship Task Force, and the Virginia Healthcare-associated Infection Advisory Group.

    In Amy’s candidacy statement for SIDP Board Member at Large she shared that “I have personally treasured SIDP’s networking and education opportunities. Importantly, I value the comradery with colleagues who face the same challenges I do in infectious diseases pharmacotherapy. I am continually impressed by the enthusiasm and commitment of fellow members. I look forward to the opportunity to give back to SIDP”  

    Amy was a wonderful colleague, mentor, and leader across our ID pharmacy community.  She was a quiet achiever and her work was highly impactful.   Amy was also very private about her illness, and we all respected her wishes.  As her Chairperson Don Brophy, Pharm.D., M.Sc., FCCP, BCPS said, “She simply wanted to be known for her work in the field of infectious diseases epidemiology, and this will indeed be her legacy.”

    And finally, from her long-time mentor and friend, Ron Polk – “Amy showed a very strong interest in infectious diseases when she was a Pharm.D. student at Virginia Commonwealth University. When she expressed her interest in an ID fellowship at VCU I was thrilled. And at some point, when I became department chair, Amy was my first hire to add to the program. We enjoyed many productive years as colleagues and friends. Since my retirement 9 years ago, Amy continued to collaborate with members of the ID division at VCU as well as those outside of VCU. Amy has made important contributions to the stewardship literature, as well as having secured substantial funding from CDC. Finally, Amy was one of the most kind and thoughtful persons I have met. She will be missed by everyone fortunate enough to have gotten to know her. And I have lost a friend.” 

    From your SIDP family, thank you Amy, you will be dearly missed by all of us. 

    Jason, Susan, Kerry, Emily, Warren, Doug, and Julie

    Society of Infectious Diseases Pharmacists Board of Directors

  • 26 Sep 2019 2:00 PM | David Ha (Administrator)

    CMS has issued its long awaited Conditions of Participation.  They are requiring all hospitals to have implemented an antibiotic stewardship program within 6 months of the final rule.

    Click here for more information

  • 17 Sep 2019 5:00 AM | David Ha (Administrator)

    SIDP co-sponsors two sessions at IDWeek October 2-6, 2019 in Washington DC.

    The first session is entitled "Experience and Challenges with Vancomycin Monitoring by AUC" with speakers  William L. Musick, PharmD and Jennifer Le, PharmD, MAS, moderated by Jason Pogue, PharmD, BCPS, BCIDP and Vincent Tam, PharmD.

    The second session is entitled "Optimizing PK/PD of New Antibiotics Against MDR Organisms" with speakers Marc H. Sheetz, PharmD, MSc, Kamilia Abdelraouf, PhD, Alexander Lepak, MD, moderated by Vincent Tam, PharmD, and Elizabeth Hirsch, PharmD.

  • 13 Sep 2019 5:00 AM | David Ha (Administrator)

    SIDP and the Infectious Diseases PRN co-sponsor a focus session entitled "Power Gaps in Stewardship: Decision Making for Diagnostics and Transitions of Care" with speakers John A. Bosso, PharmD, FCCP, FIDP, Nick Mercuro, PharmD, and Stephanie Harding, PharmD, BCPS-AQ ID with moderator Whitney J. Nesbitt, PharmD at the ACCP Annual Meeting October 26-29, 2019 in New York, NY.

    Learn More about this session and how to attend the ACCP Annual Meeting
  • 09 Sep 2019 5:00 AM | David Ha (Administrator)

    In August, SIDP partnered with Pharmacy Times through their Strategic Alliance Program. Though this partnership, SIDP will extend its mission to a broader pharmacist audience and expand its educational offerings. Additionally, an SIDP member will serve on the Pharmacy Times advisory editorial board.

    Learn more about this partnership

  • 06 Sep 2019 8:22 AM | David Ha (Administrator)

    SIDP signed on to a letter of support, along with the  American Academy of Allergy, Asthma & Immunology and 14 other organizations, encouraging the FDA to.expedite the approval of products that can be used for penicillin skin testing.

    The letter can be accessed here

  • 16 Aug 2019 10:07 AM | Anonymous
    SIDP is supportive of S.2172, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019. This bipartisan legislation seeks to increase Medicare reimbursement for specified antibiotics through removal of qualified antibiotics from the Diagnosis-Related Group (DRG). In order to participate, hospitals must have an antibiotic stewardship program in place that is consistent with the CDC Core Elements of Hospital Antibiotic Stewardship Programs. The legislation would also require participating hospitals to report antibiotic use and resistance through the CDC National Healthcare Safety Network Antimicrobial Use and Resistance Module.  A similar bill was introduced in the House of Representatives under H.R. 4100 on July 30, 2019.  SIDP has signed on to a letter of support with other infectious diseases organizations for both bills.

    The Strategies to Address Antimicrobial Resistance (STAAR) Act was reintroduced by Senator Sherrod Brown (D-OH). Additional information on the bill will posted when it is available at . Similar to the DISARM Act, SIDP has signed on to a letter of support with other infectious diseases organizations for both bills.


  • 16 Aug 2019 10:05 AM | Anonymous

    CMS Published their Finalized FY2020 Inpatient Prospective Payment System (IPPS) Ruling on August 2nd.  Although there were no new incentives for antimicrobial stewardship, they did increase the new technology add-on payment (NTAP) for certain antimicrobials from 50% to 75%. In addition, there is a new ID rapid diagnostic test that met the criteria for an NTAP payment. CMS is also finalizing an alternative NTAP pathway for antimicrobials with a Qualified Infectious Diseases (QIDP) designation. The pre-publication version is available here but a concise summary is available here.

    However, despite the lack of mention of ASP in the IPPS ruling, CMS did announce in June that the timeline has been extended by 1 year for publication of the long-awaited Conditions of Participation requirements for antibiotic stewardship programs in acute care and critical access hospitals including critical access hospitals. This deadline has been extended given extensive feedback received by individuals and professional societies including SIDP. It is now anticipated the final rule will be published on or before June of 2020. Read the full update at the link here

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Membership gives you more

  • Access exclusive opportunities
  • Connect with colleagues
  • Attend networking events


Society of Infectious Diseases Pharmacists • 110 E. Schiller Street, Suite 230, Elmhurst, IL 60126
(331) 248-7888
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software